News
Novo Nordisk issues profit warning
Digest more
Novo Nordisk cut its full-year guidance as U.S. sales continue to be hurt by copycat versions of its blockbuster Wegovy ...
Obesity drugmaker Novo Nordisk warned on Tuesday that full-year sales and operating profit would grow less than previously ...
U.S.-listed shares of Novo Nordisk sank in premarket trading Tuesday after the Danish drugmaker cut its full-year outlook and ...
The announcement came amid a slump in the company's share price and investor concerns about its experimental drug pipeline ...
Novo Nordisk announces a leadership transition as Lars Fruergaard Jørgensen welcomes new CEO Doug Doustdar. Doustdar aims to ...
Since the US Food and Drug Administration (FDA) implemented a ban on ‘compounded’ versions of Wegovy on 22 May, new ...
Some patients reluctantly shifted to save money while others have appealed for coverage of Zepbound after having experienced ...
A federal court ruled in Mylan's favor, finding no infringement of Novo's patent tied to Wegovy, rejecting direct, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback